Non-Small Cell Lung Cancer

Drug Name: Augtyro Active Ingredient: repotrectinib Indication: To treat ROS1-positive non-small cell lung cancer Approval Date: 11/15/2023 Company: Bristol-Myers Squibb Company More: https://accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf

The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can get their…